Methotrexate (MTX) is the widely agreed upon first-choice second-line agent to treat juvenile idiopathic arthritis (JIA), up to 75% of JIA patients in recent registries have used MTX at some time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback